Rifaximin in therapy of inflammatory bowel disease

Czech version

Authors: Lukáš M.
Authors‘ workplace: Klinické a výzkumné centrum pro idiopatické střevní záněty, Klinické centrum ISCARE a. s. a 1. LF UK v Praze
Published in: Gastroent Hepatol 2021; 75(1): 51-54
Category:
doi: https://doi.org/10.48095/ccgh202151

Sources

1. DuPont HL. Review article: the antimicrobial effects of rifaximin on the gut microbionta. Aliment Pharmacol Ther 2016; 43(Suppl 1): 3–10. doi: 10.1111/ apt.13434.

2. Cheng J, Shah YM, Ma X et al. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther 2010; 335(1): 32–41. doi: 10.1124/ jpet.110.170225.

3. Prantera C, Lochs H, Campieri M et al. Antibiotic treatment for Crohn’s disease: results of a multicentre, double blind, randomized, placebo controlled trial with rifaximin. Aliment Pharmacol Ther 2006; 23(8): 1117–1125. doi: 10.1111/ j.1365-2036.2006.02879.x.

4. Ďuricová D, Lukáš M, Bortlík M. Rifaximin v terapii Crohnovy nemoci. Výsledky studie GRACE 02. Ces a Slov Gastroent a Hepatol 2010; 64(3): 31–36.

5. Prantera C, Lochs H, Grimaldi M et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn’sdisease. Gastroenterology 2012; 142(3): 473–481.doi: 10.1053/ j.gastro.2011.11.032.

6. Townsend CM, Parker CE, MacDonald JK et al. Antibiotics for induction and maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2019; 2(2): CD012730. doi: 10.1002/ 14651858.CD012730.pub2.

7. D’Haens GR, Vermeire S, Van Aschee G et al. Therapy of metronidazole and azathioprine to prevent postoperative recurrence of Crohn’s disease: a controlled randomized trial. Gastroenterolohy 2008; 135(4): 1123–1129. doi: 10.1053/ j.gastro.2008.07.010.

8. Gionchetti P, Rizzello F, Ferrieri A et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dis Dis Sci 1999; 44(6): 1220–1221. doi: 10.1023/ a:1026648812439.

9. Riegler R, Russo MI, Carratú R et al. Clinical and therapeutic considerations in the treatment of nonspecific abdominal disorders in patienst with quiescent ulcerative rectocolitis: preliminary notes on treatment with rifaximin. Eur Rev Med Pharmacol 1992; 14: 9–14.

10. Isaacs KL, Sandler RS, Abrue M et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2007; 13(10): 1250–1255. doi: 10.1002/ ibd.20187.

11. Shen B, Remzi FH, Lopez AR et al. Rifaximin for maintenance therapy in antibiotic dependent pouchitis. BMC Gastroenterol 2008; 8: 26. doi: 10.1186/ 1471-230X-8-26.

12. Gionchetti P, Rizzello F, Venturi A et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999; 13(6): 713–718. doi: 10.1046/ j.1365-2036.1999.00553.x.